Visual Perceptual Learning Based Digital Therapeutics for Stereopsis in Intermittent Exotropia

Sponsor
Nunaps Inc (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT06117813
Collaborator
(none)
54
4
2
7.6
13.5
1.8

Study Details

Study Description

Brief Summary

This study evaluates the efficacy and safety of visual perceptual learning for improving stereopsis in intermittent exotropia. Half of participants will receive visual perceptual training using the Nu.T. The other half will not receive any training because there is no standard treatment for decreased stereopsis in intermittent exotropia.

Condition or Disease Intervention/Treatment Phase
  • Device: Nu.T
  • Other: No-Treatment Control
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
54 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Efficacy and Safety of the Nu.T for Improving Impaired Stereopsis Caused by Intermittent Exotropia : Multi Center, Randomized, Single-blind (Evaluator), Prospective Confirmatory Study
Anticipated Study Start Date :
Nov 13, 2023
Anticipated Primary Completion Date :
Jun 30, 2024
Anticipated Study Completion Date :
Jun 30, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Nu.T

Nu.T, 5 times a week for 8 weeks.

Device: Nu.T
Participants receive visual perceptual training using the Nu.T software.

Other: No-treatment Control

No-treatment was administered during control period.

Other: No-Treatment Control
No-treatment was administered during control period.

Outcome Measures

Primary Outcome Measures

  1. Changes in (log) arc second of stereopsis from Baseline to 8 weeks [8 weeks]

    Stereopsis will be evaluated by a Titmus Dot Test.

Secondary Outcome Measures

  1. Proportion of subjects showing improved stereopsis at 8 weeks compared to baseline [8 weeks]

    Improved stereopsis means more than 2 steps increase in Titmus Dot Test.

  2. Changes of Stereopsis based on Titmus Symbol Test from baseline to 8 weeks [8 weeks]

    Stereopsis will be evaluated by Titmus Symbol Test.

  3. Changes of Stereopsis based on Distance Randot Stereotest from baseline to 8 weeks [8 weeks]

    Stereopsis will be evaluated by Distance Randot Stereotest.

  4. Changes of strabismus angle from baseline to 8 weeks [8 weeks]

    Strabismus angle will be evaluated by distance and near-field.

  5. Changes of convergence capability score from baseline to 8 weeks [8 weeks]

    Convergence capability will be evaluated in distance and near-field by LACTOSE System. The scores by LACTOSE System range from 0 to 4.

  6. Changes of visuo-motor function from baseline to 8 weeks. [8 weeks]

    Visuo-motor function will be evaluated by the Bruininks-Oseretsky Test of Motor Proficiency Second Edition (BOT-2) test.

Eligibility Criteria

Criteria

Ages Eligible for Study:
6 Years to 15 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Intermittent Exotropia patients aged 6 to 15

  • Patients with decreased stereopsis above 50 arc seconds in Titmus Dot Test

  • Able to use the Virtual Reality(VR) device

  • Patient or legally authorized representative has signed the informed consent form

Exclusion Criteria:
  • Incomitant strabismus patient with impaired eye movement

  • Patients with amblyopia (Maximal corrective vision of one eye is less than 0.8 or maximal corrective vision both eyes more than two lines of difference)

  • History of ophthalmic surgery

  • Patient who has undergone or is currently undergoing cover treatment within one month for the purpose of treating strabismus or amblyopia

  • Scheduled for ophthalmic surgery during the clinical trial participation period (8 weeks in the treatment group as of the registration date, Maximum 16 weeks in the control group as of the registration date)

  • Difficult to understand and perform the stereopsis test.

  • Abnormal Retinal Correspondence

  • Patient with neurological abnormalities other than strabismus

  • History of premature birth

  • Participating in other clinical trial

  • Any other condition that, in the opinion of the investigator, precludes participation in the trial

Contacts and Locations

Locations

Site City State Country Postal Code
1 Inje University Ilsan Paik Hospital Goyang Korea, Republic of
2 Asan Medical Center Seoul Korea, Republic of
3 Konkuk University Hospital Seoul Korea, Republic of
4 Nowon Eulji Medical Center, Eulji University Seoul Korea, Republic of

Sponsors and Collaborators

  • Nunaps Inc

Investigators

  • Study Chair: Yeji Moon, MD, PhD, Asan Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Nunaps Inc
ClinicalTrials.gov Identifier:
NCT06117813
Other Study ID Numbers:
  • NNS-IXTS-01
First Posted:
Nov 7, 2023
Last Update Posted:
Nov 7, 2023
Last Verified:
Oct 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 7, 2023